TEDxASU Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TEDxASU's estimated annual revenue is currently $8.1M per year.(i)
  • TEDxASU's estimated revenue per employee is $155,000

Employee Data

  • TEDxASU has 52 Employees.(i)
  • TEDxASU grew their employee count by 16% last year.

TEDxASU's People

NameTitleEmail/Phone
1
VP, ResearchReveal Email/Phone
2
Head DeliveryReveal Email/Phone
3
Director TherapeuticsReveal Email/Phone
4
DirectorReveal Email/Phone
5
Director in vivo translational biologyReveal Email/Phone
6
Co-founder and Chief Scientific OfficerReveal Email/Phone
7
People and Operations ManagerReveal Email/Phone
8
Team Lead, Translational BiologyReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
Senior Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is TEDxASU?

Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast's prime biotech hub in South San Francisco.

keywords:N/A

N/A

Total Funding

52

Number of Employees

$8.1M

Revenue (est)

16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.5M526%N/A
#2
$4.2M544%$166.7M
#3
$8.7M568%N/A
#4
$11.6M57-10%N/A
#5
$8.8M572%N/A